• Minicabecera3



"Development of a new Advanced Therapy Product using genetically modified stem cells for the treatment of Inflammatory Lung Diseases"

Project code: IG-2013/0000926
Call Identifier: GAITEK 2013 & 2014


Project funded by the Department of Economic Development and Competitiveness of the Basque Government, under the program GAITEK 2013: Program to support projects to develop new products, and by the European Regional Development Fund (ERDF).

The principal objective of ERISTEM is to develop a new advanced therapy product from adult adipose stem cells (ASC) genetically modified, capable of reducing lung inflammation and at the same time regenerate lung tissue damage in inflammatory pulmonary diseases such as acute lung injury (ALI) and its most severe condition, the acute respiratory distress syndrome (ARDS). The study is based on previous group studies, in which, ASC have been genetically modified to secrete and express an anti-inflammatory protein with therapeutic potential in inflammatory lung diseases.

Hence, the technologic aim of this project is to obtain ASC capable of over-expressing anti-inflammatory proteins to strengthen their already well known capacities. Therefore, ERISTEM is expected to develop a potentially cellular therapy to regulate and modulate lung inflammation to reduce or avoid tissue damage.